Cargando…

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)

Detalles Bibliográficos
Autores principales:	Priyadarshini, Masoom, Deshpande, Gaurav, Tiwana, Simran K, Le, T. Kim, Garrison, Sean, Awan, Farrukh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430214/ http://dx.doi.org/10.1097/01.HS9.0000973656.86771.99

Ejemplares similares

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL
por: Awan, Farrukh T., et al.
Publicado: (2022)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
por: Gulrajani, Michael, et al.
Publicado: (2023)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
por: Shah, Bijal, et al.
Publicado: (2023)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
por: Loschi, Michael, et al.
Publicado: (2023)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
por: Benner, Brooke, et al.
Publicado: (2021)

Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models
por: Bertram, Katrin, et al.
Publicado: (2021)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
por: Turetsky, Anna, et al.
Publicado: (2014)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
por: von Hundelshausen, Philipp, et al.
Publicado: (2021)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
por: Lee, Eun, et al.
Publicado: (2020)

Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
por: Deng, Jing, et al.
Publicado: (2017)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
por: Ariza, Yuko, et al.
Publicado: (2019)

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j8u3vno129aqfk10aqbb7o7man